Movement Alert｜Veradermics, Inc. Overnight Rise 11.38%, clinical progress and cash runway remained the core support

Market Focus10-20

On October 20, Veradermics, Inc. rose 11.38% Overnight, trading at $136.2 per share, with turnover of $185.9 thousand.

The move was linked to continued market focus on the company’s lead candidate VDPHL01 and its relatively strong cash position.

Previously disclosed results showed VDPHL01 met all primary and key secondary endpoints in a phase 2/3 trial for male pattern hair loss. In a phase 2 study in female pattern hair loss, most participants showed improvement after six months, with no treatment-related serious adverse events or cardiac adverse events reported. On the financial side, the company previously reported about $819.9 million in cash and marketable securities, which management said could fund operations through 2030. Those updates continue to underpin investor expectations for the late-stage dermatology developer.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment